Liver cancer is a common malignant tumor with poor prognosis. The present study sought to identify potential signatures that can predict the prognosis of patients with liver cancer.
Background Liver cancer is a common malignant tumor, with a 15-17% 5-year survival rate [1, 2] . The prognosis of patients with liver cancer is poor due to the high frequency of postoperative recurrence and metastasis [3] . Surgery is still the main treatment strategy. However, liver cancer patients are usually diagnosed at advanced stages, so they often miss the optimal opportunity for surgical resection [4] . Furthermore, liver cancer is highly resistant to conventional chemotherapy and radiation therapy [5] [6] [7] . Currently, clinicopathologic prognostic factors include TNM stage, tumor size, microvascular invasion, tumor rupture, underlying cirrhosis, and multifocality [8] .
In addition to these traditional clinical prognostic factors, genetic biomarkers are novel indicators of liver cancer diagnosis and prognosis [9] . Molecular biomarkers can help predict patient prognosis [10, 11] , but there is still a lack of biomarkers for clinical management of liver cancer. Therefore, it is necessary to adopt a comprehensive approach to identify novel tumor biomarkers and explore potential molecular mechanisms.
A large number of noncoding RNAs (ncRNAs), such as miRNAs with 22-25 nucleotides and lncRNAs with over 200 nucleotides, play significant regulatory roles in many diseases, including cancers [12, 13] . miRNAs can regulate the expression of target genes at the post-transcriptional level [14] . According to the ceRNA hypothesis, lncRNA acts as a "sponge" of miRNAs, indirectly regulating mRNA function [15] . Genomic profiling of liver cancer using the TCGA database [13] has identified some dysregulated ncRNAs associated with poor prognosis. For example, overexpression of lncRNA HOXD-AS1 competitively binds to miR-130a-3p, which prevents SOX4 from undergoing miRNAmediated degradation, thereby activating EZH2 and MMP2 expression and promoting liver cancer metastasis [16] . lncRNA MIR31HG inhibits liver cancer proliferation and metastasis via sponging miR-575 to modulate ST7L expression [17] . However, there is incomplete understanding of the role of lncRNAs and miRNAs in liver cancer based on high-throughput detection.
In the present study, using RNA-seq data from TCGA, we constructed the ceRNA regulatory networks. Furthermore, our findings revealed that SNHG1 and C2orf48 are potential biomarkers for predicting clinical outcomes for patients with liver cancer.
Material and Methods

Data processing
The clinical information and RNA-seq data (level 3) of patients with liver cancer were retrieved from the TCGA-Liver Hepatocellular Carcinoma database (TCGA-LIHC; https://tcgadata.nci.nih.gov/tcga/). The RNA-seq data are based on the Illumina HiSeq RNA-seq and Illumina HiSeq miRNA-seq platforms. After removing patients with incomplete clinical information, a total of 389 patients with liver cancer were included in our study. The clinical information included age, sex, histologic grade, clinical stage, risk factors, and neoplasm status.
The gene expression profiles, miRNA data, and clinical information were also downloaded from the TCGA database. The raw RNA-seq reads, including mRNAs, miRNAs, and lncRNAs, were preprocessed and normalized with the trimmed mean of M-values (TMM) method.
Differential expression analysis
The differentially expressed analysis was performed using edgeR package in R [18] . The mRNAs, miRNAs, and lncRNAs with false discovery rate (FDR) <0.05 and |log 2 fold change (FC)| ³2 were considered to be differentially expressed. Volcano plots were plotted using the ggplot2 package in R. The heat map was generated using the pheatmap package in R.
Construction of the ceRNA network
Firstly, differentially expressed lncRNA-miRNA relationships were predicted by miRcode (http://www.mircode.org/) [19] . Then, differentially expressed miRNA targeted mRNA prediction was performed based on TargetScan (http://www.targetscan.org/), miRTarBase (http://mirtarbase.mbc.nctu.edu. tw/) and miRDB (http://www.mirdb.org/) [20, 21] . Only differentially expressed mRNAs mentioned by the above 3 databases were considered as targeted differentially expressed mRNAs. After that, the ceRNA network was constructed by matching lncRNA-miRNA and miRNA-mRNA relationships. Finally, the ceRNA network was visualized using the Cytoscape software in R (version 3.5.1; https://cytoscape.org/) [22] .
Functional enrichment analysis of differentially expressed mRNAs in the ceRNA network
To explore potential biological processes enriched by differentially expressed mRNAs in the ceRNA network, gene ontology (GO) analysis was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID) package in R. The GO terms include biological process (BP), cellular component (CC), and molecular function (MF). Furthermore, we accessed the Kyoto Encyclopedia of Genes and Genomes (KEGG) using the ClusterProfiler package in R [23] . P value <0.05 was considered significantly enriched.
Statistical analysis
The correlation between the expression level of lncRNA SNHG1 and patient survival time was assessed by univariate and multivariate Cox regression analysis. Overall survival analysis of differentially expressed mRNAs, miRNAs, and lncRNAs was performed with the Kaplan-Meier method using the survival package in R [24] . P value <0.05 was considered statistically significant.
Results
Identification of differentially expressed mRNAs, miRNAs, and lncRNAs for liver cancer
Differential expression analyses of mRNAs, miRNAs, and lncRNAs were performed by comparing liver cancer and normal tissues using the TCGA-LIHC cohort, with FDR <0.05 and |log 2 FC| ³2 as the thresholds. There were 1014 upregulated and 57 downregulated lncRNAs, there were 222 upregulated and 28 downregulated miRNAs, and 1717 upregulated and 205 downregulated mRNAs were identified for liver cancer tissues. The heat map clearly displayed the differential expression patterns of lncRNAs, miRNAs, and mRNAs in liver cancer, as shown in Figure 1A -1C. Volcano plots show the distribution of these differentially expressed lncRNAs, miRNAs, and mRNAs in Figure 1D -1F.
ceRNA network construction
After identification of the differentially expressed lncRNAs, miRNAs, and mRNAs in liver cancer, lncRNA-miRNA and miRNA-mRNA relationships were predicted using online databases. lncRNAs can interact with miRNAs through miRNA-response elements (MREs). We first predicted 649 lncRNA-miRNA relationship pairs using the miRcode database, and the miRDB, miRTarBase, and TargetScan databases were used to predict the mRNA targets of miRNAs. Based on integration of results from these 3 databases, 242 common differentially expressed mRNAs were identified ( Figure 2 ). After matching lncRNA-miRNA and miRNA-mRNA relationships, the lncRNA-miRNA-mRNA ceRNA network was built and visualized using Cytoscape (version 3.5.1). There were 94 lncRNAs, 94 mRNAs, and 57 miRNAs in the ceRNA regulatory network ( Figure 3A ). Then, we extracted the 2 lncRNAs (SNHG1 and C2orf48) with the most nodes in the ceRNA network. In the ceRNA network, SNHG1 had 13 nodes and C2orf48 had 12 nodes. Differential expression analysis results showed that SNHG1 (logFC=2.424595645; p value=3.00E-24; FDR=3.20E-22) and C2orf48 (logFC=2.157457859; p value=5.50E-13; FDR=8.42E-12) were both upregulated in liver cancer tissues (logFC=2.424595645; p value=3.00E-24; FDR=3.20E-22). The SNHG1-regulatory and C2orf48-regulatory ceRNA sub-networks were established. In the SNHG1-regulatory ceRNA sub-network, there were 10 upregulated and 2 downregulated miRNAs, and 28 upregulated and 7 downregulated mRNAs ( Figure 3B ). In the C2orf48-regulatory ceRNA sub-network, there were 10 upregulated and 2 downregulated miRNAs, and 30 upregulated and 3 downregulated mRNAs ( Figure 3C ).
Functional enrichment analysis
To further explore potential biological processes and pathways enriched by differentially expressed mRNAs in the ceRNA network, functional enrichment analyses were performed. The top 50 mRNAs with the largest fold change are shown in Figure 4A . The top 5 GO terms enriched by differentially expressed mRNAs -embryonic organ development, embryonic skeletal system development, embryonic skeletal system morphogenesis, regionalization and skeletal system morphogenesis -were visualized ( Figure 4B ). Moreover, the top 5 CC, MF, and BP terms were embryonic organ development, skeletal system morphogenesis, embryonic skeletal system development, regionalization, embryonic skeletal system morphogenesis, transcription factor complex, midbody, pronucleus, mitotic spindle, spindle, core promoter proximal region DNA binding, core promoter binding, chromatin binding, HMG box domain binding, and mRNA binding ( Figure 4C, 4D ). Moreover, we performed KEGG enrichment analysis of differentially expressed mRNAs in the ceRNA network. The results revealed that these mRNAs were mainly enriched in pathways closely related with liver cancer: cell cycle, pathways in cancer, microRNAs in cancer, p53 signaling pathway, hepatitis B, progesterone-mediated oocyte maturation, PI3K-Akt signaling pathway, transcriptional misregulation in cancer, MAPK signaling pathway, and viral carcinogenesis ( Figure 5 ).
Correlations between specific signatures (SNHG1 and C2orf48) and overall survival in liver cancer
Kaplan-Meier curves were produced to determine the relationships between the differentially expressed mRNAs, lncRNAs, and miRNAs in the ceRNA network. In Figure 6 , the high expression of lncRNAs (SNHG1, C2orf48) had shorten survival time than the low expression in 3-year and 5-year survival analysis ( Figure 6A -6D). The 2 miRNAs -hsa-miR-195 and hsa-miR-93 -were related to overall survival. High hsa-miR-93 expression was associated with worse clinical outcomes than was low expression in 3-year and 5-year survival analysis ( Figure 6E, 6F ). hsa-miR-195 expressed at a low level was associated with shorter survival time than was high expression in 3-year and 5-year survival analysis ( Figure 6G , 6H).
Upregulated SNHG1 and C2orf48 were associated with clinicopathological characteristics of liver cancer
Correlation analysis showed that SNHG1 had a negative correlation with miR-195 (correlation coefficient =-0.303 and p value=1.217e12) ( Figure 7A ). In addition, C2orf48 had a negative correlation with miR-195 and miR-93 (correlation coeffi-cient=-0.28 and p value £0.001; correlation coefficient=-0.26 and p value £0.001, respectively) ( Figure 7B , 7C). We also found that SNHG1 and C2orf48 were both associated with histologic grade (Figure 8 ). Table 1 shows the relationship between SNHG1 and clinical features of patients with liver cancer in TCGA. The results showed that SNHG1 expression was closely correlated with histologic grade (p<0.001). To investigate whether SNHG1 and C2orf48 are independent risk factors for liver cancer, we performed univariate and multivariate analyses. The results showed that SNHG1 expression was positively associated with liver cancer (HR (95% CI): 0.721 (0.459-0.893); p value=0.032 (Table 3 ). C2orf48 (HR (95% CI): 1.298 (0.936-1.8), p value=0.041) was associated with prognosis of liver cancer patients (Table 4 ). Therefore, our results suggest that SNHG1 and C2orf48 are risk factors for liver cancer.
Discussion
Liver cancer is a common malignant cancer worldwide, but there are no currently known prognostic biomarkers. In our study, we identified SNHG1 and C2orf48 as risk factors for liver cancer based on analysis of the TCGA-LIHC cohort [25] .
In the present study, using RNA-seq data of liver cancer, differentially expressed mRNAs, miRNAs, and lncRNAs were identified. After matching the relationship pairs of lncRNA-miRNA and miRNA-mRNA, we constructed the ceRNA network. SNHG1 and C2orf48 with the most nodes were selected to construct the A B C C21orf62  ADRA2B  DIRAS3  LRRC55  DACH1  PITPNM3  SFRP1  LIFR  AVPR1A  MRO  CPEB3  ESR1  PROK2  EGR1  FOS  FOSB  SOCS3  PTGS2  EGR2  RND3  BMP10  GPM6A  HHIP  CXCL12  NTF3  HMGA2  HOXD1  DLX5  HOXA10  TRIM71  IGF2BP3  ZIC2  SIX1  HOXC13  FOXG1  SALL3  HAPLN1  SLC6A15  ALX1  ALPI  TM4SF20  CLVS2  PCDHA1  IBSP  SSX5  MUC15  MAGEA12   6  4  2  0  - Log-rank method was used to assess the survival differences between the 2 groups. X axis is overall survival time and Y axis represents survival function.
ceRNA sub-networks. KEGG enrichment analysis revealed that the differentially expressed mRNAs in the network were mainly involved in the following pathways: cell cycle, pathways in cancer, microRNAs in cancer, p53 signaling pathway, hepatitis B, PI3K-Akt signaling pathway, transcriptional misregulation in cancer, MAPK signaling pathway, and viral carcinogenesis. It has been confirmed that hepatitis B infection increases the risk of liver cancer [26, 27] . Furthermore, the p53 signaling pathway, PI3K-Akt signaling pathway, and MAPK signaling pathway play critical roles in liver cancer [28] [29] [30] . Therefore, pathways enriched by differentially expressed mRNAs are closely correlated with liver cancer.
SNHG1 has been confirmed to be associated with large tumor size, poor differentiation, and aggressive BCLC stage. Moreover, highly expressed SNHG1 predicts poor outcomes of patients with liver cancer [31] [32] [33] [34] . Our results are consistent with previous studies. In the present study, we found that high SNHG1 expression was associated with worse prognosis than was low expression in 3-year and 5-year survival times. Additionally, we found that the expression level of SNHG1 was only correlated with histologic grade. Univariate and multivariate analyses results suggested that SNHG1 is an independent risk factor for liver cancer. In addition, miR-195 was downregulated in the ceRNA network. Correlation analysis confirmed that SNHG1 had a negative correlation with miR-195, suggesting there is a regulatory relationship between SNHG1 and miR-195. Previous research has reported that miR-195 is downregulated in liver cancer and is inversely correlated with liver tumor size [35] [36] [37] . As a tumor suppressor, miR-195 can inhibit liver cancer cell proliferation and migration [35] [36] [37] . Consistent with previous research, our results revealed that low-level expression of miR-195 contributed to shorter survival time compared with high expression in 3-year and 5-year follow-up.
The function of lncRNA C2orf48 in liver cancer remains unclear. In this study, we found that C2orf48 was highly expressed in liver cancer, and the 3-year and 5-year overall survival analyses suggested that highly expressed C2orf48 was associated with shorter survival time compared with low expression. We analyzed the relationship between C2orf48 and clinical features with liver cancer patients in the TCGA-LIHC cohort. We found that C2orf48 was correlated with histologic grade of liver cancer, and C2orf48 expression had a positive correlation with histologic grade, which suggests that overexpressed C2orf48 can lead to progression of liver cancer. A previous study has reported that C2orf48 is associated with overall survival in oral squamous cell carcinoma [38] . Intriguingly, it has been confirmed that C2orf48 is significantly associated with liver cancer patient prognosis [39] , and this is consistent with our results. Univariate and multivariate analyses showed that C2orf48 is a risk factor for liver cancer. In the ceRNA regulatory network, we found C2orf48-miR-93 and C2orf48-miR-195 relationship pairs. The correlation analysis revealed that C2orf48 had a negative correlation with miR-93 and miR-195. Therefore, we inferred that miR-195 could be simultaneously regulated by C2orf48 and SNHG1. miR-93 promotes cell proliferation, invasion, and metastasis in liver cancer [40] [41] [42] . In the present study, miR-93 was upregulated in liver cancer, and survival analyses confirmed that high miR-93 expression contributes to worse clinical outcomes than its low expression in 3-year and 5-year follow-up.
Taken together, our results show that SNHG1 and C2orf48 are potential biomarkers for predicting clinical outcomes for liver cancer patients. Furthermore, our results suggest that miR-195 is regulated by SNHG1 and C2orf48, and miR-93 is targeted by C2orf48. However, our conclusions need to be verified by further research.
Conclusions
Our results show that SNHG1 and C2orf48 are differentially expressed in liver cancer tissues. Based on the ceRNA network, SNHG1-miR-195 and C2orf48-miR-93 relationships were identified. Survival analysis results revealed that SNHG1 and C2orf48 were correlated with prognosis of liver cancer patients. Univariate and multivariate Cox regression analyses showed that SNHG1 and C2orf48 could be risk factors for liver cancer. Therefore, our findings suggest that SNHG1 and C2orf48 are potential biomarkers for predicting clinical outcomes for patients with liver cancer.
